Open-Label Extension of Lecanemab Supports Safety in Early Alzheimer’s
Physician's Weekly,
Effects on amyloid reduction persisted for up to 2…
Effects on amyloid reduction persisted for up to 2…
An experimental Alzheimer’s disease drug called BAN2401 has generated intriguing additional results in a a Phase II clinical…